Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few
years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic
malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine
kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose
a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical
research with nanoparticles and their use in melanoma field.
Keywords: Cancer, classification, melanoma, nab-paclitaxel, nanoparticles.
Rights & PermissionsPrintExport